ArticleClinical, cosmetic and investigational dermatology2025
IL-4, IL-13, TNF-α and IFN-γ Downregulate CLDN8 Expression Through Activating JAK Signaling Pathway in HaCaT Cells.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the impact of IL-2 cytokine family on skin barrier function: pathophysiology and therapeutic strategies.Molecular biology reports · 2026Review
- Hotspots and Emerging Trends in JAK Inhibitor Therapy for Vitiligo: A Bibliometric Analysis (2015-2025).Journal of inflammation research · 2026Article
- Population-Level Burden of Dermatitis and the Effects of Moxibustion and Capsaicin on Pruritus and JAK/STAT Signaling in Atopic Dermatitis: A Multilevel Study.Mediators of inflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tight junctions (TJs) are important for skin barrier function. Claudin-8 (CLDN8), a member of TJs, was indicated decreased in several RNA sequencing studies in dermatitis conditions. Methods: Bioinformatics analysis was performed to extract CLDN8 mRNA expression from atopic dermatitis (AD) related datasets in the Gene Expression Omnibus. CLDN8 protein expression was detected in AD lesions and healthy control skin tissues using immunohistochemistry staining (IHC). Cldn8 expression was detected in MC903-induced AD-like mouse model. AD-related cytokines with or without Janus kinase (JAK) inhibitor were added to HaCaT cells, and CLDN8 expression was detected by quantitative Polymerase Chain Reaction (qPCR). Results: CLDN8 mRNA expression is decreased in AD lesions and MC903-induced AD-like mouse model. Downregulation of CLDN8 mRNA expression is alleviated after dupilumab or crisaborole treatment. CLDN8 protein was not detected by IHC in human or mouse skin tissues. Interleukin (IL)-4, IL-13, tumor necrosis factor (TNF)-α and interferon (IFN)-γ downregulated CLDN8 mRNA expression in HaCaT cells through activating JAK. Conclusion: CLDN8 mRNA is decreased in AD lesions, and the decreased CLDN8 is alleviated along with therapy. Skin tissues might not express CLDN8 protein. AD-related cytokines including IL-4, IL-13, TNF-α and IFN-γ could downregulate CLDN8 mRNA expression through activating JAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.